Sustainable Innovation in Biopharma: Aligning Therapeutic Progress with Environmental Responsibility
Aliasgar Shahiwala, Professor, Department of Pharmaceutical Sciences, College of Pharmacy, Dubai Medical University
This dialogue examines how the biopharmaceutical sector must reconcile its mission of healing with the imperative of planetary stewardship. From green synthesis and biodegradable systems to climate-resilient manufacturing, this conversation maps the path toward a future in which therapeutic ingenuity coexists in harmony with environmental responsibility and global equity.
1. Sustainable innovation often requires systemic change. What structural or cultural shifts within biopharma organisations are essential to genuinely align R&D with environmental responsibility?
To genuinely align R&D with environmental responsibility, biopharma organisations must embrace systemic structural and cultural transformations. Structurally, integrating comprehensive environmental metrics directly into R&D processes enables tracking and management of ecological impacts throughout a product's lifecycle. Additionally, organisations should adopt methodologies like Life Cycle Assessment (LCA) to systematically evaluate and minimise environmental footprints from early-stage research through commercial production. Establishing dedicated sustainability-focused units or centers of excellence can drive scalable innovation in environmental practices. Culturally, empowering internal sustainability champions and realigning incentive structures to reward environmentally conscious decisions fosters an innovation culture rooted in sustainability.
2. You mention green synthesis as a critical pathway. Can you elaborate on the latest advancements in green chemistry that have real-world applicability in drug development today?
Recent advancements in green chemistry with direct applicability to drug development include the expanded use of biocatalysis, which facilitates chemical transformations under mild conditions, often yielding fewer byproducts and higher selectivity. Notably, the integration of biocatalysis with continuous flow processing has proven transformative, enhancing reaction efficiency, scalability, and environmental performance.
The shift toward greener solvents, such as water, supercritical CO₂, and ionic liquids, continues to reduce dependency on hazardous organic solvents. These alternatives not only lower toxicity but also improve the sustainability profile of synthetic processes.
Flow chemistry, in particular, enables precise reaction control and consistent product quality, making it ideal for pharmaceutical applications. Its ability to streamline synthesis, reduce waste, and scale efficiently aligns closely with regulatory and industry goals for greener manufacturing.
3. Biodegradable delivery systems are gaining traction. How far are we from mainstream adoption, and what are the barriers—technical, regulatory, or economic—that still need to be overcome?
Technically, achieving predictable degradation kinetics and consistent, controlled drug release remains complex. These parameters are highly sensitive to physiological variables such as pH, enzymatic activity, and temperature at the site of administration, which can influence polymer breakdown and, in turn, affect drug bioavailability and therapeutic outcomes.
Regulatory barriers also play a significant role. Biodegradable systems are often classified as combination products, subject to both pharmaceutical and medical device regulations. This dual-pathway classification can complicate the regulatory process, requiring manufacturers to comply with standards such as ISO 13485 and adhere to FDA or EMA guidelines. Extensive preclinical and clinical data are typically required to demonstrate not only safety and efficacy but also consistency in degradation and release profiles.
Economically, the cost of biodegradable systems is higher compared to conventional delivery platforms. This is due to the use of specialised biodegradable polymers (e.g., PLGA, PCL), stringent manufacturing controls, and complex formulation processes. Moreover, scaling up production while maintaining quality, reproducibility, and regulatory compliance remains a key obstacle.
4. Climate-resilient manufacturing is a relatively new but increasingly urgent concept. Could you share examples of technologies or frameworks that are helping make biopharma manufacturing more adaptable and sustainable?
Climate-resilient manufacturing is vital for biopharma’s sustainability, leveraging advanced technologies and strategic frameworks. Single-use technologies (SUTs), including disposable bioreactors, significantly reduce water and energy use, improving efficiency and adaptability. Digital twins and advanced analytics enable real-time monitoring, predictive maintenance, and resource optimisation, enhancing operational resilience. Integration of renewable energy sources, like solar and wind, reduces greenhouse gas emissions, decreasing reliance on fossil fuels. Additionally, climate intelligence frameworks proactively address climate risks across supply chains, protecting production continuity and compliance with environmental standards. Collectively, these innovations help biopharma companies adapt effectively to environmental challenges while ensuring a more sustainable and resilient manufacturing ecosystem.
5. In your view, how does the industry reconcile the high energy and resource demands of biologics and mRNA-based therapies with the need for sustainability? Are there environmentally optimised models emerging?
Reconciling the high resource demands of biologics and mRNA-based therapies with sustainability requires industry-wide adoption of optimised models. Process intensification techniques, such as continuous bioreactors, significantly reduce energy use and waste. Single-use technologies also improve efficiency by eliminating resource-intensive cleaning processes. Integrating renewable energy sources, like solar and wind power, is increasingly prevalent to cut emissions from production. Digital twins and advanced analytics facilitate real-time optimisation, enhancing resource management and predictive maintenance capabilities. Furthermore, sustainable approaches specifically tailored to mRNA production, including improved energy practices and eco-friendly waste management, are gaining momentum. Together, these innovations offer viable pathways toward maintaining therapeutic effectiveness while substantially reducing the biopharma industry's environmental footprint.
6. What role do regulatory agencies play in driving or hindering sustainable practices within the biopharma industry? Are there specific global policies or standards that are paving the way?
Regulatory agencies are pivotal in steering the biopharmaceutical industry toward sustainable practices. The World Health Organisation (WHO) has issued a call for action urging global regulatory bodies to adopt innovative practices that prioritise sustainability and reduce environmental impact. This initiative underscores the urgent need for regulatory frameworks that support the development and distribution of environmentally friendly pharmaceuticals.
In the European Union, the Corporate Sustainability Reporting Directive (CSRD) mandates large corporations, including pharmaceutical companies, to disclose sustainability risks and their impact on people and the environment. Such policies compel companies to integrate environmental considerations into their operations, fostering transparency and accountability.
Furthermore, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) works to harmonize global regulatory standards, facilitating the adoption of sustainable practices across borders. These collective efforts by regulatory bodies are instrumental in embedding sustainability into the core of biopharmaceutical development and manufacturing processes.
7. Collaboration is often a catalyst for transformation. Are there any cross-sector or academia-industry partnerships you find particularly promising in advancing both therapeutic efficacy and ecological responsibility?
Cross-sector and academia-industry collaborations are proving vital in driving both therapeutic innovation and ecological responsibility. A prime example is AION Labs, a consortium including AstraZeneca, Merck KGaA, Pfizer, Teva, and Amazon Web Services, which leverages artificial intelligence to streamline drug discovery processes with an emphasis on sustainability.
The Division of Signal Transduction Therapy (DSTT) at the University of Dundee exemplifies academic-industry synergy, partnering with companies like Pfizer and GlaxoSmithKline to accelerate research on protein kinases while fostering resource-efficient methodologies.
Another notable initiative is the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry, which encourages sustainable approaches across the drug development lifecycle by integrating academic insights and industrial scalability.
These collaborations align with global sustainability goals, marking a meaningful step toward greener, more responsible pharmaceutical development.
8. As a scientist deeply involved in pharmaceutical innovation, how do you personally evaluate the environmental impact of a research initiative or product pipeline? Are there metrics or frameworks you recommend?
I prioritise evaluating environmental impact through standardised and quantitative frameworks. Life Cycle Assessment (LCA), aligned with ISO 14040/44 standards, offers a holistic view, analysing environmental effects from raw material sourcing to end-of-life disposal.
I also recommend specific metrics:
Process Mass Intensity (PMI): assesses resource efficiency by measuring the total mass of inputs relative to the active product.
E-Factor: quantifies waste generated per unit of product, making it useful for benchmarking synthetic routes.
Carbon Footprint Analysis: helps identify stages with high greenhouse gas emissions, informing optimisation strategies.
Combining these tools allows for a comprehensive understanding of a product pipeline’s sustainability profile.
9. From your academic lens, how can pharmacy and biotech curricula evolve to instill sustainability consciousness in the next generation of scientists and pharmaceutical leaders?
Pharmacy and biotech curricula must integrate environmental stewardship as a foundational element. This includes embedding planetary health and eco-pharmacovigilance principles into core subjects, highlighting the environmental implications of pharmaceutical production, use, and waste.
Initiatives like the Sustainability in Pharmacy Education (SPE) Group are actively developing structured frameworks to guide this transformation. Leading institutions, such as the University of Huddersfield, have set benchmarks by integrating sustainability across their Master of Pharmacy programs. Additionally, regulatory bodies like the UK's General Pharmaceutical Council (GPhC) have updated their education standards to emphasize climate change and environmental sustainability, urging academic institutions to reflect these priorities in their curricula.
By embedding these principles through interdisciplinary teaching, experiential learning, and competency-based assessments, academic programs can equip students with the tools to lead sustainable innovation in the pharmaceutical and biotech industries.
10. Looking ahead, what is your vision of a truly sustainable biopharma ecosystem? How different will it look from today, and what foundational changes must occur to realise that vision?
A truly sustainable biopharma ecosystem integrates environmental stewardship into core strategic decision-making, transforming research, manufacturing, and distribution. It relies heavily on energy-efficient manufacturing, renewable energy, circular economy practices, and transparent ESG reporting for accountability. Collaborative innovation across academia, industry, and regulatory bodies, exemplified by initiatives like the Innovative Medicines Initiative (IMI), accelerates sustainable advancements. Additionally, regulatory agencies must offer supportive policies and incentives to drive industry-wide adoption. Ultimately, such foundational changes ensure therapeutic innovations not only enhance human health but also minimise ecological impact, creating long-term environmental, social, and economic value.
11. Finally, what message would you like to share with fellow researchers and industry stakeholders who are still hesitant to embrace sustainability as a core value rather than a compliance metric?
To colleagues and stakeholders who have yet to fully embrace sustainability, I encourage you to see it as an exciting opportunity rather than merely a compliance requirement. Sustainability unlocks innovation, inspires groundbreaking ideas, and enhances our ability to make meaningful contributions to society and the planet. By prioritising environmental responsibility, we elevate the purpose and impact of our work, strengthening trust among patients, investors, and communities. Together, we have the unique chance to shape a future where therapeutic breakthroughs go hand-in-hand with ecological health, creating lasting value and a legacy we can all be proud of.
Author Bio
.jpg)
Aliasgar Shahiwala is a Professor at the College of Pharmacy, Dubai Medical University. He holds both master's and doctoral degrees in Pharmaceutics from The Maharaja Sayajirao University of Baroda, India, and has completed postdoctoral research at Northeastern University, USA. A recognised Highly Cited Researcher, Dr. Shahiwala has authored numerous peer-reviewed publications and edited eight scientific books. He actively contributes to the advancement of pharmaceutical sciences through his editorial roles in several leading international journals.
